Dog hip dysplasia care options

Start with diagnosis and life stage

Hip dysplasia is developmental instability of the hip joint. Examination and appropriately obtained radiographs help define laxity, arthritis, pain, and whether another orthopedic or neurologic condition is contributing.

A growing puppy with hip laxity faces different options than a mature dog with established osteoarthritis. Ask whether referral to a board-certified veterinary surgeon is time-sensitive.

Build the non-surgical foundation

Maintaining a lean body condition reduces unnecessary joint load. Controlled exercise and rehabilitation can support strength and function, while slippery floors, stairs, and unsuitable activity can make daily life harder.

A multimodal plan may also include veterinary pain medication, anti-NGF therapy, PSGAG treatment, omega-3-rich therapeutic nutrition, and other condition-specific options. Product choice and monitoring depend on the individual dog.

• Use rugs or runners for traction.
• Choose shorter, consistent activity over boom-and-bust exercise.
• Ask a rehabilitation professional for a dog-specific strengthening plan.
• Track standing, stairs, sleep, walks, and recovery after activity.
• Review every medication and supplement together for interactions and duplication.

Understand the surgical pathways

Juvenile pubic symphysiodesis and double or triple pelvic osteotomy are considered only for selected young dogs within specific developmental windows. Total hip replacement can restore more normal joint mechanics in appropriate mature patients. Femoral head ostectomy removes painful bone-on-bone contact but does not recreate a normal joint and requires rehabilitation.

The best choice depends on age, size, arthritis, anatomy, health, activity goals, surgeon experience, aftercare, cost, and expected function.

Where emerging therapies fit

A peptide discussion should not replace diagnosis, weight management, rehabilitation, established analgesia, or a surgical opinion when one is warranted. For investigational options such as BPC-157 or TB-500, controlled clinical evidence in pet dogs remains insufficient to treat marketing claims as proven outcomes.